Adam Berman

Despite clear benefits of initiating hemodialysis with an arteriovenous fistula--including lower mortality, less reinterventions and lower health care costs—few patients in the US do so. Venova Medical is developing the next generation of vascular access systems that will address patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for reintervention.

Harmonic Bionics is a commercial-stage robotics and digital health company that aims to unlock human functional capabilities through robotics. Our flagship product, Harmony SHR®, is a bilateral upper extremity exoskeleton that works with a patient’s scapulohumeral rhythm (SHR) to enable natural, comprehensive arm and shoulder therapy for those living with neurological and musculoskeletal movement impairments. Harmony SHR is a bilateral, upper extremity exoskeleton dynamically designed to provide unique value in three areas of practice: neuroscience and movement science research, movement disorder assessment, and rehabilitation. Harmony’s multi-plane movements and bilateral design open up new research possibilities, while using precise motion and effort sensing to achieve objective assessment. All of the system’s data capabilities enable researchers and caregivers to optimize the treatment process for patients suffering from movement disorders by measuring functionality at baseline and throughout the recovery process. Harmony’s different modes of therapy also help address patients throughout the care continuum, from highly-impaired patients with no motor function to progressing patients in a post-acute setting or an outpatient rehabilitation facility.

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.

Alleviant Medical is a medical device company developing potential therapies for congestive heart failure.

Despite clear benefits of initiating hemodialysis with an arteriovenous fistula--including lower mortality, less reinterventions and lower health care costs—few patients in the US do so. Venova Medical is developing the next generation of vascular access systems that will address patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for reintervention.

Harmonic Bionics is a commercial-stage robotics and digital health company that aims to unlock human functional capabilities through robotics. Our flagship product, Harmony SHR®, is a bilateral upper extremity exoskeleton that works with a patient’s scapulohumeral rhythm (SHR) to enable natural, comprehensive arm and shoulder therapy for those living with neurological and musculoskeletal movement impairments. Harmony SHR is a bilateral, upper extremity exoskeleton dynamically designed to provide unique value in three areas of practice: neuroscience and movement science research, movement disorder assessment, and rehabilitation. Harmony’s multi-plane movements and bilateral design open up new research possibilities, while using precise motion and effort sensing to achieve objective assessment. All of the system’s data capabilities enable researchers and caregivers to optimize the treatment process for patients suffering from movement disorders by measuring functionality at baseline and throughout the recovery process. Harmony’s different modes of therapy also help address patients throughout the care continuum, from highly-impaired patients with no motor function to progressing patients in a post-acute setting or an outpatient rehabilitation facility.

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.

Alleviant Medical is a medical device company developing potential therapies for congestive heart failure.

TVA Medical, Inc., headquartered in Austin, Texas, is developing minimally invasive therapies for end-stage renal disease and other potential applications, such as peripheral vascular disease. More information is available at www.TVAMedical.com.